The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
The aim is to create new genomics solutions that could combat cancer and advance market access
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Subscribe To Our Newsletter & Stay Updated
